Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Bujanda

Showing results (401-410 of 423) with videos related to

Pageof 43
Sort By:
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 15, 2025
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO RegistryLaura Palomino, Marta Velasco Rodríguez-Belvís, María José Casanova, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA RegistryManuel Barreiro-de Acosta, Yamile Zabana, Laura Nieto-García, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel DiseaseMaría José Casanova, Maria Chaparro, Begoña Molina, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Pageof 43

Showing results (401-410 of 423) with videos related to

Sort By:
Pageof 43
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 15, 2025
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO RegistryLaura Palomino, Marta Velasco Rodríguez-Belvís, María José Casanova, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA RegistryManuel Barreiro-de Acosta, Yamile Zabana, Laura Nieto-García, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel DiseaseMaría José Casanova, Maria Chaparro, Begoña Molina, et al.
Hepatology (Baltimore, Md.)|February 2, 2026
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Jinyoung Byun, Caitlin J VanLith, et al.
United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Pageof 43